Updated Aug 6 at 3:23pm ET.
Follow Hologic to never miss an important update.
Private equity firms Blackstone and TPG are reportedly looking to buy the company's surgical unit for more than 4 billion dollars. This division focuses on tools for minimally invasive procedures, which is a steady business but different from the company's core focus on diagnostic testing and breast imaging.
Selling this unit would give the company a large pile of cash to focus on its most profitable areas. The business already makes a lot of money from its diagnostic test kits, and 4 billion dollars would allow it to either buy back more of its own shares or acquire smaller companies that fit better with its main health screening and testing technology.
Source: Reuters
Analysts have recently downgraded the stock in a series of moves spread across late 2025 and early 2026. Most analysts are split with 18 bullish and 24 neutral ratings, and the average target of $79 suggests about 4% upside.
The company has a very reliable habit of beating analyst targets, though it did hit a rare snag with a miss earlier this year.
